Foscarnet induction therapy for cytomegalovirus retinitis in aids: Comparison of twice-daily and three-times-daily regimens

Journal of Acquired Immune Deficiency Syndromes

Volumn 5, Issue , 1992, Pages S18-S24

  Katlama, Christine ^a   Dohin, Elisabeth ^a   Caumes, Eric ^a   Cochereau Massin, I ^b   Brancon, Christiane ^a   Robinet, Martin ^b   Rogeaux, Olivier ^a   Dahan, Robert ^c   Gentilini, Marc ^a  

^a Service de R?animation M?dicale et des Maladies Infectieuses   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c Astra France ^*  (France)

Author keywords

AIDS; CMV retinitis; Foscarnet induction B.I.D; Foscarnet induction T.I.D; Penile ulceration; Renal impairment

Indexed keywords

FOSCARNET;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CYTOMEGALOVIRUS INFECTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; PENIS; RETINITIS; ULCER; VOMITING;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTIVIRAL AGENTS; COMPARATIVE STUDY; CYTOMEGALOVIRUS INFECTIONS; DRUG ADMINISTRATION SCHEDULE; DRUG TOLERANCE; FEMALE; FOSCARNET; HUMAN; MALE; MIDDLE AGE; PHOSPHONOACETIC ACID; RETINITIS;

CUCUMBER MOSAIC VIRUS; CYTOMEGALOVIRUS;

EID: 0026648206     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Jacobson MA, Mills J. Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1988; 108:585-94.
2. Henderly DE, Freeman WR, Smith RE, Causey D, Rao NA. Cytomegalovirus retinitis as the initial manifestation of the acquired immunodeficiency syndrome. Am J Ophthalmol 1987; 103:316-20.
3. Holland GN, Pepose JS, Petit TH, et al. Acquired immunodeficiency syndrome. Ocular manifestations. Ophthalmology 1983; 90:859-73.
4. Palestine AG, Rodrigues MM, Macher AM, et al. Ophthalmologic involvement in acquired immunodeficiency syndrome. Ophthalmology 1984; 91:1092-9.
5. Jabs D, Enger C, Bartlett J. Cytomegalovirus retinitis and acquired immunodeficiency syndrome. Arch Ophthalmol 1989; 107:75-80.
6. Collaborative DHPG Study Group. Treatment of serious cytomegalovirus infections with 9-1 (l, 3-dihydroxy-2-propoxymethyl)guanine in patients with AIDS and other immunodeficiencies. N Engl J Med 1986; 314:801-5.
7. Laskin OL, Stahl-Bayliss CM, Kalman CM, et al. Use of ganciclovir to treat serious cytomegalovirus infections in patients with AIDS. J Infect Dis 1987; 155:323-7.
8. Buhles WC, Mastre BJ, Tinker AJ, et al. Ganciclovir treatment of life- or sight-threatening cytomegalovirus infection: experience in 314 immunocompromised patients. Rev Infect Dis 1988; 10(suppl 3):S495-505.
9. Helgestrand E, Eriksson B, Johansson NG, et al. Phosphonoformate, a new antiviral compound. Science 1978; 201:819-21.
10. Wahren B, Oberg B. Reversible inhibition of cytomegalovirus replication by phosphonoformate. Intervirology 1980; 14:7-15.
11. Oberg B. Antiviral effects of phosphonoformate (PFA, foscarnet sodium). Pharmacol Ther 1983; 19:387-415.
12. Sundquist B, Oberg B. Phosphonoformate inhibits reverse transcriptase. J Gen Virol 1979; 45:273-81.
13. Sandstrom EG, Byington RE, Kaplan JC, Hirsch MS. Inhibition of human T cell lymphotropic virus type III in vitro by phosphonoformate. Lancet 1985; 2:1480-2.
14. Wondrak EM, Lower J, Kurth R. Inhibition of HIV 1-RNA dependent DNA polymerase by phosphonoformic acid and other drugs. J Antimicrob Chemother 1988; 21:151-61.
15. Gaub J, Pedersen C, Poulsen AG, et al. The effect of foscarnet (phosphonoformate) on human immunodeficiency virus isolation, T cell subsets, and lymphocyte function in AIDS patients. AIDS 1987; 1:27-33.
16. Walmsley S, Chew E, Read SE, et al. Treatment of cytomegalovirus retinitis with trisodium phosphonoformate hexahydrate (foscarnet). J Infect Dis 1988; 157:564-72.
17. Jacobson MA, O’ Donnell JJ, Mills J. Foscarnet treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. Antimicrob Agents Chemother 1989; 33:736-41.
18. LeHoang P, Girard B, Robinet M, et al. Foscarnet in the treatment of CMV retinitis in acquired immunodeficiency syndrome. Ophthalmology 1989; 96:865-74.
19. Fanning MM, Read SE, Benson M, et al. Foscarnet therapy of cytomegalovirus retinitis in AIDS. J Acq Immun Defic Synd 1990; 3:472-9.
20. Aweeka F, Gambertoglio J, Mills J, Jacobson MA. Pharmacokinetics of intermittently administered intravenous foscarnet in the treatment of acquired immunodeficiency syndrome patients with serious cytomegalovirus retinitis. Antimicrob Agents Chemother 1989; 33:742-5.
21. Sjovall J, Karlsson A, Ogenstadt S, Sandstrom E, Saarimaki M. Pharmacokinetics and absorption of foscarnet after intravenous and oral administration to patients with human immunodeficiency virus. Clin Pharmacol Ther 1988; 44:65-73.
22. Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. N Engl J Med 1992; 326:213-20.
23. Fegueux S, Salmon D, Picard C, Sauvage C, Longuet P, Desmoulins T. Penile ulcerations with foscarnet [Letter]. Lancet 1990; l:547.
24. Moyle G, Nelson M, Barton SE, et al. Penile ulcerations with foscarnet [Letter]. Lancet 1990; 1:547.
25. Deray G, Martinez F, Katlama C, et al. Foscarnet nephrotoxicity: mechanism, incidence and prevention. Am J Nephrol 1989; 9:316-21.
26. Deray G, Katlama C, Dohin E. Prevention of foscarnet nephrotoxicity [Letter]. Ann Intern Med 1990; 113:332.
27. Beaufils M, Deray G, Katlama C, et al. Foscarnet and crystals in glomerular capillary lumens [Letter]. Lancet 1990; 2:755.
28. Eriksson B, Schinnazi R. Combination of 3'-azido-3'-deoxythymidine (zidovudine) and phosphonoformate (foscarnet) against human immunodeficiency virus type I and cytomegalovirus replication in vitro. Antimicrob Agents Chemother 1989, 33:663-9.
29. Kong X, Zhu Q, Ruprecht R, et al. Synergistic inhibition of human immunodeficiency virus type I replication in vitro by two drugs and three drugs combination of 3'-azido 3'-deoxythy-midine, phosphonoformate and 2', 3'-dideoxythymidine. Antimicrob Agents Chemother 1991; 35:2003-11.
30. Jacobson M, Van Der Horst C, Causey D, Dehlinger M, Haftier R, Mills J. In vivo additive antiretroviral effect of combined zidovudine and foscarnet therapy for human immunodeficiency virus infection. J Infect Dis 1991; 163:1219-22.